HOPE Declaração

Leituras recomendadas

Faça o download da declaração de consenso em inglês [PDF]

Appelbaum, P. S. (2022). Psychedelic research and the real world. Nature, 609(7929), S95-S95.

Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology, 36(10), 1100-1117.

Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Añaños, K., Chindoy, M. E., … & Sacbajá, A. (2023). Ethical principles of traditional indigenous medicine to guide western psychedelic research and practice. The Lancet Regional Health–Americas, 18.

Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, meaningfulness, and the “proper scope” of medicine: continuing the conversation. Cambridge Quarterly of Healthcare Ethics, 1-7.

Devenot, N., Tumilty, E., Buisson, M., McNamee, S., Nickles, D., & Ross, L. K. (2022). A Precautionary Approach to Touch in Psychedelic-Assisted Therapy. Bill of Health.

Earp and Savulescu (2021). Love Drugs: The Chemical Future of Relationships. Stanford, CA: Redwood Press.

Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., … & Prideaux, E. (2023). Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLOS ONE, 18(10), e0293349.

Fogg, C., Michaels, T. I., de la Salle, S., Jahn, Z. W., & Williams, M. T. (2021). Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Experimental and Clinical Psychopharmacology, 29(5), 539.

Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D., & Spriggs, M. J. (2024). When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. Neuroethics, 17(1), 3.

Jacobs, E., Yaden, D. B., & Earp, B. D. (2023). Toward a Broader Psychedelic Bioethics. AJOB neuroscience, 14(2), 126-129.

McGuire et al. (under review). Developing an Ethics and Policy Framework for Psychedelic Clinical Care

McGuire, A. L., Lynch, H. F., Grossman, L. A., & Cohen, I. G. (2023). Pressing regulatory challenges for psychedelic medicine. Science, 380(6643), 347-350.

McMillan, R. M. (2022). Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?. Medical Humanities, 48(3), 269-272.

Neitzke-Spruill, L. (2020). Race as a component of set and setting: How experiences of race can influence psychedelic experiences. Journal of Psychedelic Studies, 4(1), 51-60.

Noorani, T. (2021). Containment matters: Set and setting in contemporary psychedelic psychiatry. Philosophy, Psychiatry, & Psychology, 28(3), 201-216.

Ortiz, C. E., Dourron, H. M., Sweat, N. W., Garcia-Romeu, A., MacCarthy, S., Anderson, B. T., & Hendricks, P. S. (2022). Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology, 214, 109127.;

Thrul, J., & Garcia-Romeu, A. (2021). Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs: Education, Prevention and Policy, 28(3), 211-214.

Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022). Preparing for the bursting of the psychedelic hype bubble. JAMA psychiatry, 79(10), 943-944.

Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022). Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics, 31(4), 464-471.